Navigation Links
Current Blood Thinners Face Tough Competition
Date:2/26/2010

Studies provide more evidence that newcomers hold mettle against warfarin, aspirin

FRIDAY, Feb. 26 (HealthDay News) -- New studies provide more proof that the mainstays of anti-clotting therapy, namely warfarin and aspirin, are facing some severe competition from newcomers.

Researchers presenting their findings during a Friday news conference at the American Stroke Association's annual meeting in San Antonio show that one new drug, dabigatran (Pradaxa), which is not yet approved in the United States, equaled warfarin for treating stroke patients, while cilostazol (Pletal), which has been approved by the U.S. Food and Drug Administration for the treatment of peripheral arterial disease (PAD), outperformed aspirin in preventing recurrent strokes.

Other researchers presented evidence that high-intensity movement exercise assisted by a robot or a human can improve functioning and quality of life in stroke survivors years after the event. It has long been thought that improvements could only be garnered in the early days following a stroke.

The Pradaxa trial included 3,623 patients with atrial fibrillation and a previous stroke who were randomized to receive warfarin, a low dose of Pradaxa (110 milligrams) twice a day or a higher dose (150 mg) of Pradaxa twice a day for about two years.

The rate of stroke or transient ischemic attack (TIA) in those taking warfarin was 2.74 percent a year and 2.32 percent a year for those taking Pradaxa, not a significant difference.

The lower dose of Pradaxa also caused less bleeding and was easier to manage than warfarin, a famously difficult drug to administer and monitor.

"In contrast to warfarin, dabigatran is given in a fixed dose twice daily independent of body weight, sex, food, whatever, and you don't need to monitor the coagulation system," study author Dr. Hans-Christoph Diener, chairman of neurology at University Hospital in Essen, Germany, said during the news conference.

"In patients who already had a transient ischemic attack or stroke and suffer from atrial fibrillation, dabigatran is as effective as warfarin," he added. "And it's much easier to handle."

Patients receiving Pradaxa had more heart attacks than those taking warfarin, but the absolute difference was small, the authors stated. Also, Pradaxa patients had higher rates of gastrointestinal bleeding.

The study was funded by Boehringer-Ingelheim GmbH, which makes this drug.

A second trial pitted the clot-busting drug Pletal against aspirin and found that Pletal was superior in preventing recurrent strokes without the bleeding complications associated with aspirin.

Among 2,700 stroke patients in the trial, those taking Pletal were 25.7 percent less likely to have a stroke than those taking aspirin. The authors had expected the stroke rate to be the same between the two groups.

"We conclude that the cilostazol is one of the options for the secondary prevention of stroke in patients who can tolerate long-term administration of this drug," said study author Dr. Yukito Shinohara, head of neurology at Tachikawa Hospital in Tokyo.

This trial was funded by Otsuka Pharmaceutical Co., Ltd, which makes cilostazol.

The final study turned to technology to help patients severely debilitated by a stroke.

"Upper extremity impairment is very common after a stroke and there are very few therapeutic options for people with chronic stroke and few studies on rehabilitation," said study author Dr. Albert C. Lo, a neurologist at the VA Medical Center and an assistant professor of neurology at Brown University in Providence, R.I.

Patients receiving high-intensity movement therapy -- either from a human or a robot -- experienced improved functioning in their arm and improved quality of life compared with patients getting "usual care."

"High-intensity movement matters for these individuals," said Lo. "Getting them to move their arm on a regular basis and practice results in a fairly modest improvement. We're not talking about curing anyone. There are modest but consistent improvements in quality of life."

The robot-assisted protocol cost about the same as conventional therapy -- about $3 a day over a year, if you exclude the actual cost of the robot.

More information

The American Stroke Association has more on stroke.



SOURCES: Feb. 26, 2010, news conference with Yukito Shinohara, M.D., head, neurology, Tachikawa Hospital, Tokyo; Hans-Christoph Diener, M.D., Ph.D., professor and chairman, neurology, University Hospital, Essen, Germany; Albert C. Lo, M.D., neurologist, VA Medical Center, and assistant professor, neurology, Brown University, Providence, R.I.


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Mesothelioma Clinical Trials List Offered by IQ Mesothelioma: Search Current Mesothelioma Treatment Options
2. Children can have recurrent strokes
3. OnlineEducation.com Announces the Addition of Fully Accredited Law and Criminal Justice Degree Programs to its Current Website Offerings
4. Current Smoking Can Worsen Lung Cancer
5. Is Obesity a Disease? Current Research, Facts, Figures, and the Pros and Cons at New ProCon.org Website
6. American Scientific CE Removed - Now Current Information
7. CAHU and NAHU Weigh in on Current Form of H. R. 3590
8. Anthem Blue Cross and Blue Shield In Missouri Urges Missouri Senators Claire McCaskill and Christopher S. Bond to Not Support the Current Senate Health Care Reform Legislation
9. Connectyx Attains Current Listing Status on Pink Sheets Exchange
10. National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short In Addressing Cancer Care Crisis
11. National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short in Addressing Cancer Care Crisis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... ... research and conference coverage on veterinary medicine, announces the launch of Veterinarian’s Money ... be packaged with the April edition of American Veterinarian™. , “We ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek , ... pursue the recent RNA methylation “gold rush” with their established portfolio of optimized ... characteristics of N6-methyladenosine, or m6A , RNA methylation has received a new ...
(Date:3/27/2017)... Los Angeles, CA (PRWEB) , ... March 27, 2017 , ... ... for men with prostate cancer, including all stages, is more than 95%. Once the ... drops drastically to less than 30%. To find out how to avoid this latter ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... entered a settlement agreement to resolve the pending litigation between itself and 1800 ... the District of Utah). , “I am thrilled to announce that we have ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... Harris Communications, ... of hearing, is bringing its latest products to the Deaf Seniors of America Conference, ... have the opportunity to meet with knowledgeable ASL friendly staff from Harris Communications and ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017 Summary This ... Bayer and its partnering interests and activities since 2010. ... an in-depth insight into the partnering activity of one of ... company reports are prepared upon purchase to ensure inclusion of ... The report will be delivered in PDF format within ...
(Date:3/27/2017)... LONDON , March 27, 2017 ... require to better understand Eli Lilly and its partnering interests ... Alliance since 2010 report provides an in-depth insight into the ... companies. On demand company reports are prepared upon ... deal and company data. The report will be ...
(Date:3/27/2017)... , March 27, 2017 ... clinical-stage pharmaceutical company specializing in the development of cannabinoid-based ... offering in the United States ... ADS representing 40 ordinary shares of the Company, ... addition, Therapix has granted the underwriters a 45-day ...
Breaking Medicine Technology: